CC 100

Drug Profile

CC 100

Alternative Names: CC100; CC100 Project ALS

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Chemigen
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 17 Feb 2017 Chemigen initiates enrolment in a phase I trial for Amyotrophic lateral sclerosis the US (NCT03049046)
  • 01 Feb 2015 Chemigen completes a phase I trial in Amylotrophic lateral sclerosis (In volunteers) in USA (NCT02050334)
  • 01 Nov 2013 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top